Description

This curriculum spans the breadth of a multi-year drug discovery program, integrating data mining, predictive modeling, and cross-functional decision-making comparable to internal R&D initiatives in biopharmaceutical organizations.

Module 1: Defining Discovery Objectives and Target Validation

Selecting disease areas based on unmet medical need, market size, and biological tractability using public and proprietary epidemiological datasets.
Integrating multi-omics data (genomics, transcriptomics, proteomics) to identify and prioritize putative drug targets with strong causal evidence.
Evaluating target druggability by assessing protein family, binding pocket characteristics, and known ligandability from structural databases.
Using Mendelian randomization to assess causal relationships between target modulation and disease outcomes, reducing late-stage attrition risk.
Mapping target expression across tissues to anticipate on-target toxicity and therapeutic index limitations.
Establishing go/no-go criteria for target progression, including genetic validation score, safety flags, and competitive landscape analysis.
Collaborating with clinical experts to align target biology with patient stratification strategies and trial feasibility.

Module 2: Sourcing and Curating High-Quality Biological Data

Assessing data provenance, versioning, and experimental protocols when integrating public databases like ChEMBL, PubChem, and GTEx.
Designing ETL pipelines to harmonize chemical structures, bioactivity measurements, and assay conditions across heterogeneous sources.
Applying structure curation rules: removing salts, standardizing tautomers, and filtering pan-assay interference compounds (PAINS).
Resolving bioactivity data inconsistencies by normalizing units (e.g., IC50 to pIC50), handling censored values, and flagging assay artifacts.
Building internal knowledge graphs that link compounds, targets, pathways, and phenotypes using controlled ontologies (e.g., ChEBI, GO, MeSH).
Establishing data access agreements and compliance protocols for restricted datasets (e.g., clinical trial data, biobanks).
Implementing audit trails and metadata logging to support regulatory reproducibility and internal peer review.

Module 3: Chemical Space Exploration and Virtual Screening

Selecting molecular fingerprint types (e.g., ECFP, MACCS) based on screening objective: similarity search vs. scaffold hopping.
Applying scaffold-based clustering to ensure structural diversity in hit selection and avoid intellectual property conflicts.
Running large-scale docking simulations using prepared protein structures from PDB or homology models with assessed reliability.
Calibrating scoring functions against known actives and decoys to reduce false positives in virtual hits.
Integrating machine learning models (e.g., random forest, GNNs) trained on historical HTS data to prioritize compounds for testing.
Setting thresholds for predicted activity and confidence to balance hit rate with experimental capacity.
Designing iterative screening cascades: starting with fast filters, progressing to more accurate but computationally expensive models.

Module 4: Hit-to-Lead Optimization with Predictive Modeling

Generating matched molecular pairs to identify structural transformations that improve potency while maintaining selectivity.
Training QSAR models with domain-appropriate validation: temporal splits, scaffold splits, and external test sets.
Estimating ADMET properties (e.g., solubility, CYP inhibition, hERG binding) using consensus models to de-risk candidates.
Optimizing synthetic accessibility scores (SAscore, SCScore) alongside potency to ensure feasible medicinal chemistry routes.
Using Pareto optimization to navigate trade-offs between potency, selectivity, metabolic stability, and logP.
Flagging compounds with structural alerts for genotoxicity or reactive metabolites using rule-based systems (e.g., DEREK, SARpy).
Integrating real-time feedback from wet-lab results to retrain models and refine compound recommendations.

Module 5: Multi-Omics Integration for Mechanism of Action Elucidation

Applying transcriptomic signature matching (e.g., CMap, LINCS) to infer compound mechanism and repurpose existing molecules.
Using proteomics data to identify off-target binding and potential toxicity pathways not captured in vitro.
Constructing gene regulatory networks from single-cell RNA-seq to model compound effects on cell states.
Validating predicted MoA with CRISPR knockout or overexpression experiments in relevant cell models.
Mapping compound-induced pathway perturbations using enrichment analysis (e.g., GSEA, Reactome) with multiple testing correction.
Integrating phosphoproteomics to identify signaling cascade effects and adaptive resistance mechanisms.
Assessing batch effects and normalization methods when combining omics datasets across labs and platforms.

Module 6: Managing Data Governance and Regulatory Compliance

Implementing role-based access controls for sensitive data (e.g., patient-derived genomics, pre-publication results).
Documenting data lineage from source to model output to satisfy FDA ALCOA+ principles for data integrity.
Archiving model training datasets and hyperparameters to support auditability and reproducibility.
Applying GDPR and HIPAA requirements when using human-derived data, including de-identification and data minimization.
Establishing data retention policies for intermediate results and failed experiments to balance storage costs and knowledge preservation.
Conducting algorithmic bias assessments when models are used for patient stratification or toxicity prediction.
Preparing validation reports for machine learning models used in regulated submissions (e.g., 21 CFR Part 11).

Module 7: Scaling Infrastructure for High-Throughput Analysis

Designing containerized workflows (e.g., Docker, Nextflow) to ensure portability across cloud and on-premise HPC environments.
Optimizing job scheduling for molecular docking or simulation workloads using Kubernetes or SLURM.
Selecting GPU instances for deep learning tasks based on model size, batch processing needs, and cost efficiency.
Implementing data caching and indexing strategies for rapid querying of billion-compound libraries.
Monitoring pipeline performance and failure rates to detect data quality issues or software regressions.
Managing version control for both code (Git) and data (DVC, Delta Lake) in collaborative development environments.
Estimating computational costs for large-scale virtual screens and securing budget approval from stakeholders.

Module 8: Cross-Functional Collaboration and Decision Governance

Facilitating joint review meetings between computational scientists, medicinal chemists, and pharmacologists to align on candidate selection.
Translating model outputs into actionable insights using visualizations that highlight structure-activity relationships and risk factors.
Documenting model limitations and uncertainty estimates to prevent overreliance on in silico predictions.
Establishing escalation paths for discrepancies between computational predictions and experimental results.
Integrating project timelines and milestone gates to synchronize computational deliverables with wet-lab cycles.
Managing intellectual property disclosure risks when publishing or presenting predictive models and novel targets.
Conducting post-mortem analyses of failed compounds to update predictive models and refine decision criteria.

Module 9: Longitudinal Monitoring and Real-World Evidence Integration

Linking preclinical predictions with clinical trial outcomes to assess model calibration and update priors.
Monitoring post-marketing safety databases (e.g., FAERS) for adverse events that may reflect off-target effects missed in silico.
Updating target validation scores as new human genetic evidence (e.g., UK Biobank, gnomAD) becomes available.
Re-evaluating compound libraries with newer models or data to identify repurposing opportunities.
Tracking competitor pipelines to assess novelty and freedom-to-operate for ongoing programs.
Integrating real-world patient data (e.g., EHRs) to refine disease endotypes and identify responsive subpopulations.
Establishing feedback loops from clinical pharmacokinetics and pharmacodynamics to refine ADMET models.